Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation
Purpose The aim of this study was to estimate the proportion of bleedings that occurred among warfarin users attributable to the concomitant use of other medications. A general approach for measuring the impact of the prescriptive inappropriateness on drug adverse outcomes at the population level is described. Methods A meta-analysis was conducted to obtain summary relative risks of bleeding associated with concurrent use of warfarin and other medications compared to warfarin use alone. A population-based investigation was performed, in an Italian cohort of cardiopathic patients aged 65 years or older, to estimate the prevalence of concurrent users of warfarin and other medicaments. The population attributable fraction was computed by combining data on summary relative risks and prevalence of concurrent users. Results Concomitant use of warfarin and cotrimoxazole, amiodarone, quinolones, macrolides, platelet aggregation inhibitors, SSRIs, NSAIDs, and lipid-lowering agents was associated with an increased risk of bleeding. The corresponding attributable fractions were 3% (95% CI 2 to 4%), 21% (1 to 41%), 21% (17 to 25%), 9% (8 to 10%), 14% (12 to 16%), 6% (5 to 8%), 10% (1 to 20%), and 8% (0 to 18%), respectively. Conclusions More than half of bleeding events occurring among frail elderly using warfarin are attributable to a concomitant use of warfarin with certain drugs. Because some of these drugs appear to be essential for the treatment/prevention of cardiovascular conditions, and their concomitant use with warfarin could be acceptable in some cases, proper INR-monitoring and warfarin dose adjustments are requested..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:74 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 74(2018), 8 vom: 07. Mai, Seite 1061-1070 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Comoretto, Rosanna Irene [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Attributable fraction |
|---|
| Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2018 |
|---|
| doi: |
10.1007/s00228-018-2467-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC206411436X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC206411436X | ||
| 003 | DE-627 | ||
| 005 | 20230511181249.0 | ||
| 007 | tu | ||
| 008 | 200819s2018 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-018-2467-8 |2 doi | |
| 035 | |a (DE-627)OLC206411436X | ||
| 035 | |a (DE-He213)s00228-018-2467-8-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Comoretto, Rosanna Irene |e verfasserin |0 (orcid)0000-0002-8601-1899 |4 aut | |
| 245 | 1 | 0 | |a Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2018 | ||
| 520 | |a Purpose The aim of this study was to estimate the proportion of bleedings that occurred among warfarin users attributable to the concomitant use of other medications. A general approach for measuring the impact of the prescriptive inappropriateness on drug adverse outcomes at the population level is described. Methods A meta-analysis was conducted to obtain summary relative risks of bleeding associated with concurrent use of warfarin and other medications compared to warfarin use alone. A population-based investigation was performed, in an Italian cohort of cardiopathic patients aged 65 years or older, to estimate the prevalence of concurrent users of warfarin and other medicaments. The population attributable fraction was computed by combining data on summary relative risks and prevalence of concurrent users. Results Concomitant use of warfarin and cotrimoxazole, amiodarone, quinolones, macrolides, platelet aggregation inhibitors, SSRIs, NSAIDs, and lipid-lowering agents was associated with an increased risk of bleeding. The corresponding attributable fractions were 3% (95% CI 2 to 4%), 21% (1 to 41%), 21% (17 to 25%), 9% (8 to 10%), 14% (12 to 16%), 6% (5 to 8%), 10% (1 to 20%), and 8% (0 to 18%), respectively. Conclusions More than half of bleeding events occurring among frail elderly using warfarin are attributable to a concomitant use of warfarin with certain drugs. Because some of these drugs appear to be essential for the treatment/prevention of cardiovascular conditions, and their concomitant use with warfarin could be acceptable in some cases, proper INR-monitoring and warfarin dose adjustments are requested. | ||
| 650 | 4 | |a Attributable fraction | |
| 650 | 4 | |a Bleeding risk | |
| 650 | 4 | |a Drug-drug interaction | |
| 650 | 4 | |a Elderly patients | |
| 650 | 4 | |a Warfarin | |
| 700 | 1 | |a Rea, Federico |4 aut | |
| 700 | 1 | |a Lucenteforte, Ersilia |4 aut | |
| 700 | 1 | |a Mugelli, Alessandro |4 aut | |
| 700 | 1 | |a Trifirò, Gianluca |4 aut | |
| 700 | 1 | |a Cascini, Silvia |4 aut | |
| 700 | 1 | |a Roberto, Giuseppe |4 aut | |
| 700 | 1 | |a Chinellato, Alessandro |4 aut | |
| 700 | 1 | |a Filippelli, Amelia |4 aut | |
| 700 | 1 | |a Corrao, Giovanni |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Springer Berlin Heidelberg, 1970 |g 74(2018), 8 vom: 07. Mai, Seite 1061-1070 |w (DE-627)129300438 |w (DE-600)121960-1 |w (DE-576)01449289X |x 0031-6970 |7 nnns |
| 773 | 1 | 8 | |g volume:74 |g year:2018 |g number:8 |g day:07 |g month:05 |g pages:1061-1070 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00228-018-2467-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 74 |j 2018 |e 8 |b 07 |c 05 |h 1061-1070 | ||